NMN/NR and Testosterone: What Women Need to Know About This Combination

What Is the Interaction Between NMN/NR and Testosterone?

No published pharmacokinetic study has directly tested NMN or NR alongside testosterone in women. The interaction risk is pharmacodynamic, meaning the two agents do not compete for the same enzyme or transporter, but they share downstream effects on blood viscosity and lipid handling that compound when used together.

Testosterone stimulates erythropoiesis through androgen-receptor signaling and suppression of hepcidin, raising red blood cell mass and hematocrit. NMN and NR raise intracellular NAD+ levels, which activates sirtuins (particularly SIRT1 and SIRT3) and PARP enzymes involved in mitochondrial biogenesis. Animal data show NAD+ repletion can independently promote erythroid progenitor differentiation, though this has not been confirmed in women at supplement doses.

CYP Enzyme Involvement

Testosterone is metabolized primarily by CYP3A4 and CYP2C19. NMN and NR are converted intracellularly through the NAD+ salvage pathway (NMN via NMNAT enzymes; NR via NRK1/NRK2) and do not appear to be substrates, inducers, or inhibitors of CYP3A4, CYP2C19, or P-glycoprotein at physiological concentrations. No CYP-mediated pharmacokinetic interaction is currently documented.

P-glycoprotein and Transporter Data

Neither NMN nor NR has been identified as a clinically significant P-gp substrate or inhibitor in human transporter studies. The FDA's drug interaction guidance lists no NMN or NR transporter flags. This absence of transporter interaction is reassuring, but it also reflects a data gap: dietary supplements are rarely subjected to the full interaction battery required of prescription drugs.

Pharmacodynamic Overlap

The clinically relevant concern sits at the pharmacodynamic level, specifically two overlapping signals:

1. Erythrocytosis. Testosterone raises hematocrit dose-dependently. A 2023 meta-analysis in JAMA found erythrocytosis occurred in approximately 4.9% of men on testosterone replacement therapy, with hematocrit rising above 54% in some cases. In women, therapeutic testosterone doses are far lower (typically 5 mg to 10 mg transdermal per day versus 50 mg or more in men), and erythrocytosis is rare but not absent. If NAD+ repletion also promotes red cell progenitor expansion, the combination could push hematocrit higher than testosterone alone.

2. Lipid effects. Testosterone lowers HDL cholesterol, particularly with oral or intramuscular forms. A 2024 randomized trial in Menopause confirmed that transdermal testosterone at female-range doses had a modest HDL-lowering effect. NMN supplementation at 900 mg per day for 12 weeks raised NAD+ metabolites and showed a neutral-to-favorable lipid signal in a small Japanese trial, but the combined lipid effect of both agents in perimenopausal women has not been studied.

Who Uses Testosterone, and Why Does This Matter for Women?

Testosterone therapy in women is not a fringe practice. The 2019 Global Consensus Statement on Testosterone Use in Women, endorsed by The Menopause Society, concluded that testosterone has a specific evidence base for hypoactive sexual desire disorder (HSDD) in postmenopausal women when dosed to physiological premenopausal levels.

Life-Stage Breakdown

Reproductive years. Women with PCOS already have androgen excess. Adding exogenous testosterone is almost never appropriate in this group, and NMN's effect on SIRT1 activity may theoretically amplify androgen signaling through deacetylation of androgen-receptor coactivators, though direct human data do not yet exist.

Perimenopause. Testosterone levels decline by roughly 50% between ages 20 and 45, independent of the menopause transition. Some clinicians prescribe low-dose testosterone off-label during perimenopause for fatigue, low libido, and cognitive symptoms. NMN is increasingly marketed to perimenopausal women as a mitochondrial support supplement, so this combination is probably the most common real-world scenario.

Post-menopause. The evidence base for testosterone in HSDD is strongest here. The APHRODITE trial showed transdermal testosterone 300 mcg per day significantly improved satisfying sexual events and desire scores in surgically menopausal women versus placebo. Women in this life stage who are also taking NMN for longevity should be the primary focus of monitoring guidance.

Surgical menopause. Bilateral oophorectomy causes an abrupt drop in both estrogen and testosterone. Women prescribed testosterone post-oophorectomy may use higher relative doses and are at greater baseline cardiovascular risk, making lipid and hematocrit monitoring especially relevant.

Sex-Specific Pharmacology: Why Women Are Not Just Small Men

Women metabolize testosterone differently than men at every level. CYP3A4 activity is modestly higher in women, meaning oral testosterone clearance is faster, which is part of why topical routes are preferred in female practice. Estrogen co-administration (as in combined HRT) induces CYP3A4 further, potentially reducing testosterone bioavailability by 20% to 30% in women on concurrent estradiol.

NMN bioavailability data in women specifically is thin. A 2022 human pharmacokinetic study in NPJ Aging showed that oral NMN 500 mg raised whole-blood NAD+ significantly, but the cohort was predominantly male. The 2023 MAIA trial enrolled postmenopausal women and showed NMN 800 mg per day for 8 weeks improved muscle insulin sensitivity without reporting sex-stratified erythroid or androgen-signaling data.

A practical framework for women combining NMN/NR with testosterone by life stage:

| Life Stage | Testosterone Indication | NMN/NR Risk Level | Priority Monitoring | |---|---|---|---| | Reproductive years (PCOS) | Rarely appropriate | Moderate (androgen amplification concern) | Total testosterone, free androgen index | | Perimenopause | Off-label libido, fatigue | Low to moderate | Hematocrit, lipids at 3 months | | Post-menopause (HSDD) | Strongest evidence base | Low to moderate | CBC, hematocrit, lipids at 3 and 6 months | | Post-oophorectomy | Common clinical use | Moderate | CBC, hematocrit, lipids, cardiovascular risk score |

Pregnancy, Lactation, and Contraception

Testosterone is absolutely contraindicated in pregnancy. The FDA label for testosterone carries a pregnancy Category X designation (under the legacy system): fetal virilization of female fetuses is documented in animal studies and case reports. If you are prescribed testosterone and are of reproductive age, reliable contraception is not optional. It is a clinical requirement before the first dose.

Women using testosterone who are trying to conceive should stop testosterone a minimum of 3 months before attempting pregnancy to allow endogenous hormonal recovery, per ACOG guidance on androgen therapy in women.

NMN and NR have no human pregnancy safety data. Animal studies have not shown teratogenicity at standard doses, but the absence of evidence is not evidence of safety. The NIH Office of Dietary Supplements notes that safety of NMN in pregnant and lactating women has not been established. Both supplements should be discontinued in confirmed pregnancy and during breastfeeding until human data exist.

Lactation transfer of testosterone is documented: androgen exposure through breast milk is a theoretical risk to nursing infants, and testosterone is generally contraindicated during lactation. NMN transfer into human breast milk has not been studied.

What the Evidence Actually Shows (And What It Does Not)

Honesty about data gaps is a clinical responsibility. Here is the evidence map as it stands in mid-2025.

What Has Been Studied

• NMN raises NAD+ in humans. Yoshino et al. (2021) in Science confirmed that oral NMN 250 mg per day for 10 weeks significantly increased skeletal muscle NAD+ metabolite levels and improved insulin sensitivity in postmenopausal women with prediabetes. This is the best female-specific NMN trial to date.
• NR similarly raises NAD+. Martens et al. (2018) in Nature Communications showed NR 1,000 mg per day for 6 weeks raised whole-blood NAD+ by approximately 60% in healthy adults.
• Testosterone at female doses is effective for HSDD. The APHRODITE trial (Davis et al., 2008) remains the landmark reference.
• Testosterone raises hematocrit. The JAMA 2023 meta-analysis referenced above quantified this in a large male cohort; female data exist primarily from case series and smaller trials.

What Has Not Been Studied

• The combined effect of NMN or NR plus testosterone on hematocrit in women.
• Whether NAD+ repletion modifies androgen-receptor sensitivity or testosterone clearance in women.
• Whether sirtuin activation by NMN/NR changes sex hormone-binding globulin (SHBG) levels, which would alter free testosterone.
• Long-term cardiovascular outcomes of the combination in perimenopausal or postmenopausal women.

Women have been historically under-represented in both NAD+ supplement trials and testosterone trials. Most erythrocytosis risk data comes from male hypogonadism studies. Extrapolating those numbers to a 52-year-old woman taking 5 mg testosterone gel and 500 mg NMN daily requires clinical judgment rather than direct evidence.

Monitoring Protocol for Women on Both Agents

Because the interaction is pharmacodynamic rather than pharmacokinetic, the management approach is surveillance rather than dose adjustment based on drug levels. Below is a practical monitoring schedule.

Before Starting Either Agent

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel
• Fasting lipid panel
• Total testosterone and free testosterone (or calculated free testosterone)
• SHBG
• Blood pressure

At 3 Months

• CBC: flag hematocrit above 48% in women (the threshold at which testosterone dose reduction is typically considered, per Endocrine Society guidelines on testosterone therapy)
• Fasting lipid panel: watch HDL, as a drop below 40 mg/dL warrants reassessment
• Testosterone trough level to confirm female-range dosing (target generally below 70 ng/dL free testosterone equivalent)

At 6 Months and Annually

• Repeat CBC, lipids, and testosterone levels
• Cardiovascular risk reassessment using validated tool (e.g., ASCVD 10-year risk calculator)
• Review NMN/NR dose and indication with prescriber

Red Flags That Warrant Stopping or Adjusting

• Hematocrit above 50% on two consecutive measurements
• New or worsening headaches, visual changes, or signs of hyperviscosity
• HDL below 35 mg/dL
• Signs of virilization: clitoral enlargement, voice deepening, or acne flare

Drug Interactions of NMN/NR Beyond Testosterone

NMN and NR have a small but growing drug interaction profile that matters for women.

Anticoagulants. NAD+ precursors activate sirtuins, which may modestly affect SIRT1-regulated clotting factors. No clinical interaction with warfarin has been confirmed, but women on anticoagulation should monitor INR more closely when starting NMN at doses above 500 mg per day.

Metformin. Metformin inhibits complex I of the mitochondrial electron transport chain, reducing NAD+ consumption and potentially blunting the metabolic effect of NMN supplementation. Women with PCOS taking metformin and NMN may see attenuated NAD+ benefit, though direct human data are absent.

Chemotherapy. Some oncologists express theoretical concern that NAD+ repletion may support cancer cell survival through DNA repair pathways. Women with active or recent breast cancer diagnoses should not self-prescribe NMN or NR without explicit oncology sign-off.

Statins. Both testosterone and statins affect lipid metabolism. Adding NMN, which has a neutral-to-favorable lipid effect in small trials, is unlikely to cause harm, but the three-way combination has not been studied.

Is This Combination Right for You?

This is not a yes-or-no answer independent of clinical context.

The combination may be appropriate if:

• You are postmenopausal with confirmed HSDD, your testosterone has been prescribed to keep levels within the physiological female range, your hematocrit is normal at baseline, and your cardiovascular risk is low.
• You are perimenopausal with documented low testosterone and your prescriber has reviewed your full medication list and ordered baseline labs.
• You understand that NMN/NR is a supplement without FDA-approved indications, and you are using it alongside, not instead of, evidence-based care.

The combination is not appropriate if:

• You are pregnant, trying to conceive, or breastfeeding. Both agents should be stopped.
• You have polycythemia vera or a known clotting disorder. Testosterone alone is high-risk; adding any agent that may further stimulate erythropoiesis compounds that risk.
• You have PCOS with androgen excess. Exogenous testosterone is contraindicated, and NMN's theoretical androgen-amplifying sirtuin effects are an additional reason to avoid it in this setting without specialist guidance.
• You have active breast cancer. Neither NMN nor testosterone has a clear safety record in this population.
• Your hematocrit is already at or above 48% on testosterone alone.

Practical Counseling Points

Your prescriber should know you are taking NMN or NR before you start testosterone therapy, and vice versa. Neither agent is benign in isolation when specific clinical conditions are present.

Dose timing does not change the pharmacodynamic interaction: taking NMN in the morning and applying testosterone gel at night does not reduce the overlapping erythroid or lipid effects.

NMN and NR are not interchangeable in terms of bioavailability pathway, though both raise NAD+. NR crosses cell membranes directly via nucleoside transporters; NMN relies partly on conversion to NR extracellularly before cellular uptake, per Grozio et al. (2019) in Nature Metabolism. Neither pathway is known to interact with testosterone's androgen-receptor mechanism.

If you are monitoring your own testosterone levels (as many women in self-directed longevity protocols do), know that NAD+ precursors do not affect standard immunoassay testosterone measurement. Your test results will not be falsely elevated or suppressed by NMN or NR.

Check your hematocrit at least once after combining these agents for 8 to 12 weeks. A value above 48% in a woman is an actionable finding regardless of symptoms.